Navigation Links
Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced
Date:4/17/2008

Disorders Program and behavioral neurologist and neuroscientist at New York-Presbyterian/Weill Cornell Medical Center, and associate professor of clinical neurology at Weill Cornell Medical College in New York City.

"This was the first placebo-controlled clinical trial of GAMMAGARD for Alzheimer's disease and the results are clearly promising," Dr. Relkin commented.

Baxter supported the study and provided GAMMAGARD LIQUID and GAMMAGARD S/D for the trial. GAMMAGARD S/D and GAMMAGARD LIQUID, marketed as KIOVIG in the European Union, contain a broad spectrum of immunoglobulins (antibodies) and are indicated as an immunoglobulin replacement therapy that boosts the immune system in patients with primary immunodeficiency disorders. The precise mechanisms of GAMMAGARD S/D and GAMMAGARD LIQUID's effects in Alzheimer's disease are not known.

"These study results reflect Baxter's support of innovative science and commitment to meeting a critical, unmet medical need," said Hartmut J. Ehrlich, MD, vice president of global research and development for Baxter's BioScience business. "While results of Baxter's mid-stage development work in Alzheimer's disease treatment are promising, further investigation in a larger Phase III study is required."

Phase II Study Design

In the double-blind, placebo-controlled Phase II study, 24 patients in the United States with mild-to-moderate Alzheimer's disease, who were maintained on standard treatment therapy, were randomly assigned to receive GAMMAGARD LIQUID (eight patients), GAMMAGARD S/D (eight patients) or saline placebo (eight patients) for six months. The study included a comparison of four dosing regimens of GAMMAGARD, with doses ranging from 0.2 g/kg every two weeks to 0.8 g/kg every month. The safety and tolerability of the treatment and clinical outcomes of 24 patients were assessed at the beginning of the study and after three and six months. The study is an ongoing, open-label study extended to 1
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013 The ... for systemic delivery of therapeutic agents has been receiving ... drug delivery showing significant promise. The crucial formulation considerations ... delivery device play a major role in the efficiency ... in the development of new formulation techniques and devices ...
(Date:5/23/2013)... de mayo de 2013  Volcano Corporation (NASDAQ: ... fabricante de herramientas de precisión para terapia guiadas ... la enfermedad vascular periférica y coronaria, anunció hoy ... enosine V asodilator I ndependent ... sesión de ensayo clínico hot line late breaking ...
(Date:5/23/2013)... Nephros, Inc. (OTC Bulletin Board: ... develops and sells high performance liquid purification ultrafilters, announced ... addition, the concurrent temporary reduction in exercise price for ... 2013. Nephros estimates that it will receive ... A portion of the proceeds will be used for ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... Calif., Sept. 27, 2011 The Wireless-Life Sciences Alliance ... 2011, where researchers from global institutions such as MIT, ... share the best new research and significant advances in ... government and industry. The conference is ...
... Sept. 27, 2011 In mid September, Harris Interactive ... for health care and which types of Medicare spending ... reduce the budget deficit.   Nearly four ... government should strengthen patients, access to home medical equipment ...
Cached Medicine Technology:Aging-in-Place Research Breakthroughs To Be Presented At Wireless Health 2011 Conference 2Aging-in-Place Research Breakthroughs To Be Presented At Wireless Health 2011 Conference 3Americans Favor Investment in Community and Home-Based Health Care, According to Harris Interactive Survey, September 2011 2Americans Favor Investment in Community and Home-Based Health Care, According to Harris Interactive Survey, September 2011 3
(Date:5/25/2013)... 2013 Radius Engineering International Inc., ... in the US and has been building concrete, ... 35 years. M.E. and President, Walton McCarthy, author ... Weapon Fundamentals and Shelter Engineering Standards, Sixth Edition, ... shelter engineering. McCarthy is considered the leading expert ...
(Date:5/25/2013)... 25, 2013 Providing patients with their best ... team of weight management professionals. But, aside from educating patients ... Diet Doc’s hCG diets also provide patients, who ... childhood like bullying, more control over their lives by achieving ... with the underlying factors of weight gain derived from earlier ...
(Date:5/25/2013)... May 25, 2013 On May 20, 2013 ... do not wish to discuss or plan for their eventual ... FuneralFinancials.com released a Must-Do List to help people ... Financials recommends, “Creating a personal fact sheet.” , While not ... financial information and personal data. It may include a ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 The ... ranging from irritable bowel syndrome (IBS) to bloating, ... among the most long-lasting, embarrassing, frustrating and difficult ... foods for digestive health have provided a ... are many factors contributing to digestive health issues, ...
(Date:5/25/2013)... York, NY (PRWEB) May 25, 2013 ... dedicated to brain cancer research and advocacy, comments on ... Extraterrestrial Physics, that shows incorporating cold atmospheric plasma into ... cells. , According to a Science Daily ... Extraterrestrial Physics (MPE), biologists and physicians demonstrated the “synergistic ...
Breaking Medicine News(10 mins):Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2
... NEW YORK, July 13 Next week, the Center for ... in six states demonstrating that attacks, harassment, discriminatory legal restrictions and stigma ... reproductive rights. The report will be released at a briefing for ... July 22 , at 12:30 p.m. in room ...
... study by researchers from the Automotive Safety Program at Riley ... online July 13, 2009 in the journal Pediatrics ... needs are doing a good job with the selection of ... using it correctly. The study, one of the first ...
... ALISO VIEJO, Calif., July 13 Bausch & Lomb announced ... Administration (FDA) to market the Crystalens HD(TM) in quarter ... intraocular lens (IOL) was first approved by the FDA in November ... the celebration of the Crystalens HD first anniversary of ...
... , , CHICAGO, July 13 ... and fair 12-month budget that does not include deep cuts to ... to override Governor,s veto of (S.B. 1197) which included cutting human services programs ... the state have begun to lay off staff and close offices. , ...
... are not cognitively impaired, study finds , MONDAY, July 13 ... could cut their odds of Alzheimer,s and other cognitive decline ... as having one to two drinks a day, the study ... a nearly 40 percent drop in dementia risk, compared with ...
... , WASHINGTON, July 13 The American ... specialists, will honor six scientists who have made significant contributions to ... Ernest Beutler Lecture and Prize, will be presented at the 51st ... , , Past ASH president ...
Cached Medicine News:Health News: Making the difficult task of transporting a child with special needs safer 2Health News:Bausch & Lomb Receives Approval of Crystalens HD in Quarter Diopter Steps 2Health News:Bausch & Lomb Receives Approval of Crystalens HD in Quarter Diopter Steps 3Health News:Illinois Human Service Providers Announce Layoffs 2Health News:Illinois Human Service Providers Announce Layoffs 3Health News:Moderate Drinking Might Guard Against Alzheimer's 2Health News:Moderate Drinking Might Guard Against Alzheimer's 3Health News:Moderate Drinking Might Guard Against Alzheimer's 4Health News:Six Researchers to Receive Prestigious Awards from the American Society of Hematology 2Health News:Six Researchers to Receive Prestigious Awards from the American Society of Hematology 3
... is an easy-to-use, automated system that enables ... assays for managing hemostatic disordersincluding D-Dimer, Von ... offers reflex and rerun testing for greater ... by our high-quality service to help your ...
... Predictable Protection Made Easy. The new generation ... effectiveness and ease of use, providing you ... SVG stenting and angioplasty procedures., ,The FilterWire ... while requiring minimal changes to technique. ...
Representing the next step in the evolution of point-of-care testing, the i-STAT 1 Analyzer uses one platform to perform glucose strip testing along with all i-STAT test cartridges....
... 4194 Bipolar over-the-wire left-heart lead is for ... steroid-eluting lead has an angled shape and ... or a stylet delivery method, giving physicians ... position the lead in a variety of ...
Medicine Products: